Integral Molecular Redefining Success in the Heart of Philadelphia By Mark TerryApril 25, 2023 Integral Molecular has cut the ribbon in its new headquarters, the first tenant in Philadelphia’s One [….]
Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine
An intensive 2-day in person meeting that delves into the latest in vaccine research, platform technologies, development and manufacturing & a meeting place for experts working within cutting-edge vaccine research [….]
Join oligo leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the oligonucleotides [….]
For more than 40 years, smallpox has not been a viral concern for the world. No cases have naturally occurred since 1977. Despite that, government agencies are worried that smallpox could become a biological weapon in the hands of terrorists and rogue states and are making preparations for such a scenario by stockpiling old medications that have been successful, as well as new, experimental therapies.
Zalgen Labs, which until late December been housed at the Germantown Innovation Center for the past eight years, is focused on developing diagnostics and therapeutics for infectious emerging viral threats that have become endemic in the far corners of the world, including diseases such as Lassa fever, Ebola and other hemorrhagic diseases.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company’s approximately 48,000 square foot research and development center (RDC) in Frederick, Md. on October 18, 2021 at 12:00 p.m. ET. The RDC is expected to support the Company’s expanding infectious disease pipeline. This includes providing internal capacity to discover and develop vaccines and antivirals intended to support U.S. pandemic preparedness.
Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
SEPTEMBER 30, 2021
-Additional award brings APT’s total funding from the U.S. Department of Defense to $31.2 million–
–Will support APT’s PhageBankTM clinical stage programs targeting infectious diseases-
GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases. The new funding brings the total contract awarded to APT to $31.2 million.
“We are thrilled to have the ongoing support of the DoD in the advanced development of our PhageBank™ platform to treat drug-resistant infections across multiple indications,” said Greg Merril, CEO and co-founder of Adaptive Phage Therapeutics. “We are thankful for the opportunity to collaborate with the U.S. military to create potentially lifesaving therapies for our nation’s service members.”
With the Delta variant driving over 100,000 new infections per day across the United States, the COVID-19 pandemic is far from over. While COVID continues to rage, infectious disease experts are not only battling the ongoing pandemic but are on the lookout for the next virulent threat.
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting multiple ophthalmic diseases.
